Arvinas (ARVN) Competitors

Arvinas logo
$6.57 -0.20 (-2.90%)
As of 11:56 AM Eastern
This is a fair market value price provided by Massive. Learn more.

ARVN vs. AGIO, MESO, ZBIO, MAZE, and SLS

Should you buy Arvinas stock or one of its competitors? Arvinas's main competitors and comparable companies include Agios Pharmaceuticals (AGIO), Mesoblast (MESO), Zenas BioPharma (ZBIO), Maze Therapeutics (MAZE), and SELLAS Life Sciences Group (SLS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Arvinas compare to Agios Pharmaceuticals?

Arvinas (NASDAQ:ARVN) and Agios Pharmaceuticals (NASDAQ:AGIO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings, media sentiment and valuation.

In the previous week, Agios Pharmaceuticals had 4 more articles in the media than Arvinas. MarketBeat recorded 8 mentions for Agios Pharmaceuticals and 4 mentions for Arvinas. Agios Pharmaceuticals' average media sentiment score of 0.80 beat Arvinas' score of -0.14 indicating that Agios Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Arvinas
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Agios Pharmaceuticals
2 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Arvinas has higher revenue and earnings than Agios Pharmaceuticals. Arvinas is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arvinas$262.60M1.64-$80.80M-$0.24N/A
Agios Pharmaceuticals$54.03M32.31-$412.78M-$6.32N/A

Arvinas presently has a consensus target price of $15.18, suggesting a potential upside of 130.94%. Agios Pharmaceuticals has a consensus target price of $42.13, suggesting a potential upside of 44.31%. Given Arvinas' higher probable upside, equities research analysts plainly believe Arvinas is more favorable than Agios Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arvinas
1 Sell rating(s)
3 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.50
Agios Pharmaceuticals
1 Sell rating(s)
3 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.60

Arvinas has a beta of 1.81, indicating that its share price is 81% more volatile than the broader market. Comparatively, Agios Pharmaceuticals has a beta of 0.66, indicating that its share price is 34% less volatile than the broader market.

95.2% of Arvinas shares are held by institutional investors. 7.3% of Arvinas shares are held by company insiders. Comparatively, 5.4% of Agios Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Arvinas has a net margin of -3.45% compared to Agios Pharmaceuticals' net margin of -264.76%. Arvinas' return on equity of -2.00% beat Agios Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Arvinas-3.45% -2.00% -1.43%
Agios Pharmaceuticals -264.76%-34.63%-32.04%

Summary

Arvinas beats Agios Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Arvinas compare to Mesoblast?

Mesoblast (NASDAQ:MESO) and Arvinas (NASDAQ:ARVN) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.

Mesoblast has a beta of 2.21, suggesting that its share price is 121% more volatile than the broader market. Comparatively, Arvinas has a beta of 1.81, suggesting that its share price is 81% more volatile than the broader market.

Mesoblast has higher earnings, but lower revenue than Arvinas.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mesoblast$120.25M12.80-$57.50MN/AN/A
Arvinas$262.60M1.64-$80.80M-$0.24N/A

Mesoblast has a net margin of 0.00% compared to Arvinas' net margin of -3.45%. Mesoblast's return on equity of 0.00% beat Arvinas' return on equity.

Company Net Margins Return on Equity Return on Assets
MesoblastN/A N/A N/A
Arvinas -3.45%-2.00%-1.43%

Mesoblast presently has a consensus target price of $39.00, suggesting a potential upside of 229.67%. Arvinas has a consensus target price of $15.18, suggesting a potential upside of 130.94%. Given Mesoblast's higher probable upside, equities analysts clearly believe Mesoblast is more favorable than Arvinas.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mesoblast
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
Arvinas
1 Sell rating(s)
3 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.50

In the previous week, Mesoblast had 5 more articles in the media than Arvinas. MarketBeat recorded 9 mentions for Mesoblast and 4 mentions for Arvinas. Mesoblast's average media sentiment score of -0.03 beat Arvinas' score of -0.14 indicating that Mesoblast is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Mesoblast
0 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
2 Negative mention(s)
1 Very Negative mention(s)
Neutral
Arvinas
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

1.4% of Mesoblast shares are held by institutional investors. Comparatively, 95.2% of Arvinas shares are held by institutional investors. 18.8% of Mesoblast shares are held by insiders. Comparatively, 7.3% of Arvinas shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Mesoblast beats Arvinas on 10 of the 14 factors compared between the two stocks.

How does Arvinas compare to Zenas BioPharma?

Zenas BioPharma (NASDAQ:ZBIO) and Arvinas (NASDAQ:ARVN) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, media sentiment and analyst recommendations.

Zenas BioPharma has a net margin of 0.00% compared to Arvinas' net margin of -3.45%. Arvinas' return on equity of -2.00% beat Zenas BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Zenas BioPharmaN/A -144.65% -59.83%
Arvinas -3.45%-2.00%-1.43%

Arvinas has higher revenue and earnings than Zenas BioPharma. Arvinas is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zenas BioPharma$10M186.72-$377.74M-$9.42N/A
Arvinas$262.60M1.64-$80.80M-$0.24N/A

Zenas BioPharma has a beta of -0.88, meaning that its stock price is 188% less volatile than the broader market. Comparatively, Arvinas has a beta of 1.81, meaning that its stock price is 81% more volatile than the broader market.

Zenas BioPharma presently has a consensus price target of $46.71, suggesting a potential upside of 69.67%. Arvinas has a consensus price target of $15.18, suggesting a potential upside of 130.94%. Given Arvinas' higher possible upside, analysts clearly believe Arvinas is more favorable than Zenas BioPharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zenas BioPharma
1 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.56
Arvinas
1 Sell rating(s)
3 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.50

In the previous week, Zenas BioPharma had 8 more articles in the media than Arvinas. MarketBeat recorded 12 mentions for Zenas BioPharma and 4 mentions for Arvinas. Zenas BioPharma's average media sentiment score of 0.62 beat Arvinas' score of -0.14 indicating that Zenas BioPharma is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Zenas BioPharma
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Arvinas
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

95.2% of Arvinas shares are held by institutional investors. 22.0% of Zenas BioPharma shares are held by insiders. Comparatively, 7.3% of Arvinas shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Arvinas beats Zenas BioPharma on 8 of the 15 factors compared between the two stocks.

How does Arvinas compare to Maze Therapeutics?

Arvinas (NASDAQ:ARVN) and Maze Therapeutics (NASDAQ:MAZE) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

Arvinas has a beta of 1.81, indicating that its stock price is 81% more volatile than the broader market. Comparatively, Maze Therapeutics has a beta of 2.04, indicating that its stock price is 104% more volatile than the broader market.

Arvinas has higher revenue and earnings than Maze Therapeutics. Arvinas is trading at a lower price-to-earnings ratio than Maze Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arvinas$262.60M1.64-$80.80M-$0.24N/A
Maze Therapeutics$167.50M10.81-$131.12M-$2.65N/A

Arvinas currently has a consensus target price of $15.18, suggesting a potential upside of 130.94%. Maze Therapeutics has a consensus target price of $65.50, suggesting a potential upside of 97.86%. Given Arvinas' higher probable upside, research analysts clearly believe Arvinas is more favorable than Maze Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arvinas
1 Sell rating(s)
3 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.50
Maze Therapeutics
1 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
3 Strong Buy rating(s)
3.08

In the previous week, Maze Therapeutics had 14 more articles in the media than Arvinas. MarketBeat recorded 18 mentions for Maze Therapeutics and 4 mentions for Arvinas. Arvinas' average media sentiment score of -0.14 beat Maze Therapeutics' score of -0.49 indicating that Arvinas is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Arvinas
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Maze Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

95.2% of Arvinas shares are owned by institutional investors. 7.3% of Arvinas shares are owned by company insiders. Comparatively, 5.3% of Maze Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Maze Therapeutics has a net margin of 0.00% compared to Arvinas' net margin of -3.45%. Arvinas' return on equity of -2.00% beat Maze Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Arvinas-3.45% -2.00% -1.43%
Maze Therapeutics N/A -38.39%-32.57%

Summary

Arvinas beats Maze Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Arvinas compare to SELLAS Life Sciences Group?

Arvinas (NASDAQ:ARVN) and SELLAS Life Sciences Group (NASDAQ:SLS) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, valuation, earnings, analyst recommendations, media sentiment, risk and institutional ownership.

95.2% of Arvinas shares are owned by institutional investors. Comparatively, 17.4% of SELLAS Life Sciences Group shares are owned by institutional investors. 7.3% of Arvinas shares are owned by insiders. Comparatively, 1.3% of SELLAS Life Sciences Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

SELLAS Life Sciences Group has lower revenue, but higher earnings than Arvinas. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arvinas$262.60M1.64-$80.80M-$0.24N/A
SELLAS Life Sciences GroupN/AN/A-$26.86M-$0.20N/A

Arvinas presently has a consensus price target of $15.18, indicating a potential upside of 130.94%. SELLAS Life Sciences Group has a consensus price target of $10.00, indicating a potential downside of 48.42%. Given Arvinas' stronger consensus rating and higher probable upside, analysts plainly believe Arvinas is more favorable than SELLAS Life Sciences Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arvinas
1 Sell rating(s)
3 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.50
SELLAS Life Sciences Group
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

SELLAS Life Sciences Group has a net margin of 0.00% compared to Arvinas' net margin of -3.45%. Arvinas' return on equity of -2.00% beat SELLAS Life Sciences Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Arvinas-3.45% -2.00% -1.43%
SELLAS Life Sciences Group N/A -33.96%-31.75%

Arvinas has a beta of 1.81, meaning that its stock price is 81% more volatile than the broader market. Comparatively, SELLAS Life Sciences Group has a beta of 2.73, meaning that its stock price is 173% more volatile than the broader market.

In the previous week, SELLAS Life Sciences Group had 19 more articles in the media than Arvinas. MarketBeat recorded 23 mentions for SELLAS Life Sciences Group and 4 mentions for Arvinas. SELLAS Life Sciences Group's average media sentiment score of 0.64 beat Arvinas' score of -0.14 indicating that SELLAS Life Sciences Group is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Arvinas
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
SELLAS Life Sciences Group
4 Very Positive mention(s)
2 Positive mention(s)
9 Neutral mention(s)
2 Negative mention(s)
2 Very Negative mention(s)
Positive

Summary

Arvinas beats SELLAS Life Sciences Group on 9 of the 15 factors compared between the two stocks.

Get Arvinas News Delivered to You Automatically

Sign up to receive the latest news and ratings for ARVN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ARVN vs. The Competition

MetricArvinasBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$430.27M$4.03B$7.76B$11.52B
Dividend YieldN/A3.62%2.46%4.42%
P/E Ratio-27.3723.8834.2129.69
Price / Sales1.6416.208.475.59
Price / CashN/A26.3721.9322.50
Price / Book0.844.084.303.66
Net Income-$80.80M-$22.88M$3.52B$392.29M
7 Day Performance-5.00%-7.26%-5.29%-4.21%
1 Month Performance-5.68%-6.09%-4.26%-6.68%
1 Year Performance-40.45%-6.92%-1.48%-7.19%

Arvinas Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ARVN
Arvinas
2.3014 of 5 stars
$6.57
-2.9%
$15.18
+130.9%
-36.0%$430.27M$262.60MN/A246
AGIO
Agios Pharmaceuticals
3.6261 of 5 stars
$31.38
+6.7%
$42.13
+34.2%
-30.9%$1.87B$54.03MN/A540
MESO
Mesoblast
1.8359 of 5 stars
$14.44
+1.2%
$39.00
+170.1%
-15.7%$1.86B$120.25MN/A108
ZBIO
Zenas BioPharma
3.2234 of 5 stars
$28.57
+1.1%
$46.71
+63.5%
-20.2%$1.85B$10MN/A167
MAZE
Maze Therapeutics
2.646 of 5 stars
$34.91
+2.1%
$64.45
+84.6%
+4.2%$1.85B$167.50MN/A141

Related Companies and Tools


This page (NASDAQ:ARVN) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners